Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VE202
- Development stage
- Discontinued
- Lead developer
- Vedanta Biosciences
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
VE202 is an investigational, orally administered **live biotherapeutic product** developed by Vedanta Biosciences for mild-to-moderate ulcerative colitis. It is a rationally defined consortium of 16 nonpathogenic, nontoxigenic Clostridia strains selected to restore microbiome functions associated with intestinal immune tolerance, regulatory T-cell induction, production of beneficial immunoregulatory metabolites, conversion of primary to secondary bile acids, and epithelial-barrier support. In the randomized Phase 2 COLLECTiVE202 trial, VE202 did not achieve its Week 8 endoscopic-response primary endpoint versus placebo, although it was generally well tolerated without treatment-related serious adverse events. ([vedantabio.com](https://www.vedantabio.com/press-release/vedanta-biosciences-announces-phase-2-study-of-ve202-in-ulcerative-colitis-did-not-meet-primary-endpoint/))
- Other names
- JNJ-72537634JNJ72537634JNJ 72537634VE202VE-202VE 202
Beyond the preview
Go deeper on VE202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VE202.